SG11201907579VA - Peptides for dry eye disease - Google Patents
Peptides for dry eye diseaseInfo
- Publication number
- SG11201907579VA SG11201907579VA SG11201907579VA SG11201907579VA SG11201907579VA SG 11201907579V A SG11201907579V A SG 11201907579VA SG 11201907579V A SG11201907579V A SG 11201907579VA SG 11201907579V A SG11201907579V A SG 11201907579VA SG 11201907579V A SG11201907579V A SG 11201907579VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- dry eye
- california
- allysta
- belmont
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
TearBreak-up Time sec} FIG. 6.0 Days 0 Day 10 5.0 L. \ \ \ I.)y (tlel, PEPT0t.N4 iCi Treatment (n=10 eyes/group; SD 0.0 * P< 0.05 vs. Dry Eye Vehicle (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WI P0 I P C T omit VIII °nolo VIII VIII om° oimIE (10) International Publication Number WO 2018/165218 Al (51) International Patent Classification: A61K 9/00 (2006.01) A61K 38/08 A61K 31/4725 (2006.01) A61K 38/10 A61K 38/04 (2006.01) A61K 38/13 (21) International Application Number: PCT/US2018/021232 (22) International Filing Date: 06 March 2018 (06.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/469,170 09 March 2017 (09.03.2017) US (71) Applicant: ALLYSTA PHARMACEUTICALS, INC [US/US]; 19 Davis Drive, Suite 102, Belmont, California 94002 (US). (72) Inventors: HSU, Henry; Allysta Pharmaceuticals, Inc., 19 Davis Drive, Suite 102, Belmont, California 94002 (US). OTVOS, Laszlo; Allysta Pharmaceuticals, Inc., 19 Davis Drive, Suite 102, Belmont, California 94002 (US). (74) Agent: SUN-HOFFMAN, Lin; P.O. Box 52048, Palo Alto, California 94303 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (2006.01) (2006.01) (2006.01) (54) Title: PEPTIDES FOR DRY EYE DISEASE 00 kt) (57) : Disclosed are ophthalmic compositions, methods for using the compositions and kits comprising the compositions for 1-1 ----. treating dry eye in a subject in need thereof. The composition comprises at least one peptide that is an inhibitor of trans-endothelial *t migration, an analogue, variant, derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient 1-1 © for treating dry eye and ocular diseases of inflammation. O [Continued on next page] WO 2018/165218 Al MIDEDIMOMOIDEIREEMOMOHEIMIHOEHMEMNIE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762469170P | 2017-03-09 | 2017-03-09 | |
PCT/US2018/021232 WO2018165218A1 (en) | 2017-03-09 | 2018-03-06 | Peptides for dry eye disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907579VA true SG11201907579VA (en) | 2019-09-27 |
Family
ID=63447985
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907579VA SG11201907579VA (en) | 2017-03-09 | 2018-03-06 | Peptides for dry eye disease |
SG10202111732UA SG10202111732UA (en) | 2017-03-09 | 2018-03-06 | Peptides for dry eye disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202111732UA SG10202111732UA (en) | 2017-03-09 | 2018-03-06 | Peptides for dry eye disease |
Country Status (10)
Country | Link |
---|---|
US (1) | US11524045B2 (en) |
EP (1) | EP3592334A4 (en) |
JP (1) | JP2020510037A (en) |
KR (1) | KR20200004789A (en) |
CN (1) | CN110381920A (en) |
AU (1) | AU2018231180A1 (en) |
CA (1) | CA3053250A1 (en) |
IL (1) | IL269062A (en) |
SG (2) | SG11201907579VA (en) |
WO (1) | WO2018165218A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202211043D0 (en) | 2022-07-28 | 2022-09-14 | Univ Birmingham | Peptide agonist |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101244035A (en) * | 2008-02-21 | 2008-08-20 | 南京医科大学附属南京第一医院 | Cyclosporins A emulsion preparations for eyes and preparation thereof |
US20110312886A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | TGF-ß AND METHODS OF TREATING OCULAR AND OTHER DISEASES |
GB201200555D0 (en) * | 2012-01-13 | 2012-02-29 | Univ Birmingham | Peptide |
US9839671B2 (en) * | 2012-01-13 | 2017-12-12 | The University Of Birmingham | Peptide and uses therefor |
GB201312010D0 (en) | 2013-07-04 | 2013-08-21 | Univ Birmingham | Receptor Agonists |
CN115919996A (en) * | 2015-05-01 | 2023-04-07 | 雅利斯塔制药公司 | Adiponectin peptidomimetics for the treatment of ophthalmic diseases |
KR102440162B1 (en) | 2015-07-08 | 2022-09-02 | 악세로비젼, 인크. | A pharmaceutical composition comprising an integrin alpha4 antagonist for use in the treatment of an ocular inflammatory condition |
-
2018
- 2018-03-06 AU AU2018231180A patent/AU2018231180A1/en not_active Abandoned
- 2018-03-06 JP JP2019548892A patent/JP2020510037A/en active Pending
- 2018-03-06 SG SG11201907579VA patent/SG11201907579VA/en unknown
- 2018-03-06 WO PCT/US2018/021232 patent/WO2018165218A1/en unknown
- 2018-03-06 US US16/492,325 patent/US11524045B2/en active Active
- 2018-03-06 SG SG10202111732UA patent/SG10202111732UA/en unknown
- 2018-03-06 EP EP18764841.5A patent/EP3592334A4/en not_active Ceased
- 2018-03-06 CN CN201880016200.2A patent/CN110381920A/en active Pending
- 2018-03-06 CA CA3053250A patent/CA3053250A1/en active Pending
- 2018-03-06 KR KR1020197029524A patent/KR20200004789A/en unknown
-
2019
- 2019-09-02 IL IL26906219A patent/IL269062A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018231180A1 (en) | 2019-08-29 |
CN110381920A (en) | 2019-10-25 |
US20210128677A1 (en) | 2021-05-06 |
KR20200004789A (en) | 2020-01-14 |
CA3053250A1 (en) | 2018-09-13 |
WO2018165218A1 (en) | 2018-09-13 |
JP2020510037A (en) | 2020-04-02 |
US11524045B2 (en) | 2022-12-13 |
EP3592334A4 (en) | 2020-12-16 |
EP3592334A1 (en) | 2020-01-15 |
SG10202111732UA (en) | 2021-12-30 |
IL269062A (en) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201907298WA (en) | Methods and compositions for gene transfer across the vasculature | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
SG11201806542PA (en) | Anti-mica antibodies | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
SG11201910206QA (en) | Methods and compositions for treating inflammatory gastrointestinal disorders | |
SG11201910193VA (en) | Methods and compositions for treating allergic ocular diseases | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |